在老年人中诊断和治疗注意力缺陷多动性障碍 (ADHD)
Maja Dobrosavljevic1, Henrik Larsson1,2, Samuele Cortese3,4,5,6,7
1School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Expert review of neurotherapeutics
|September 19, 2023
概括
老年人注意力缺陷/多动障碍 (ADHD) 的研究不足,诊断和治疗方面存在重大差距. 本综述讨论了这一群体中ADHD的患病率,诊断挑战和基于证据的治疗选择.
科学领域:
- 老年精神病学是一门精神病学专业.
- 神经发育障碍 神经发育障碍
背景情况:
- 关于老年人注意力缺陷/多动障碍 (ADHD) 的知识存在重大差距.
- 在这个人口群体中,对ADHD的诊断和治疗存在独特的挑战.
研究的目的:
- 审查目前关于ADHD的文献,重点关注老年人.
- 检查老年人ADHD的诊断标准,查工具和差异诊断.
- 综合关于老年人多动症治疗疗效,安全性和临床指导方针的证据.
主要方法:
- 关于ADHD患病率,障碍和并发症的综合文献综述.
- 对成年ADHD的诊断标准 (DSM/ICD) 和评估工具的分析.
- 对药理治疗和老年人临床指南的经验证据的评估.
主要成果:
- 该综述涵盖了ADHD患病率,功能影响和终身伴随性疾病.
- 讨论了老年人多动症的诊断有效性和查工具.
- 介绍了关于药物反应,安全性和治疗指南的经验数据.
结论:
- 未来的诊断手册可能会包括老年人ADHD的具体说明.
- 更多的流行病学研究预计将澄清这一年龄段的ADHD患病率和负担.
- 进一步的研究,包括RCT,将为老年人ADHD干预提供基于证据的指导方针.
关键词:
注意缺陷多动障碍 (ADHD) 是一种注意缺陷多动障碍.伴随性疾病发生率.诊断 诊断 诊断 诊断 诊断 诊断功能障碍 功能障碍 功能障碍年龄较大的成年人.患病率的流行情况.治疗治疗治疗治疗治疗治疗治疗建议 治疗建议更多相关视频
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.8K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.4K
相关概念视频
Attention-Deficit/Hyperactivity Disorder
90
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
90
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Cognitive Development During Adulthood
155
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
155
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
